Possible involvement of the (pro)renin receptor-dependent system in the development of insulin resistance

Frontiers in Bioscience - Scholar

Volumn 3 S, Issue 4, 2011, Pages 1478-1485

  Rafiq, Kazi ^a   Hitomi, Hirofumi ^a   Nakano, Daisuke ^a   Ichihara, Atsuhiro ^b   Nishiyama, Akira ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

(Pro)Renin Receptor; Diabetes Mellitus; Insulin Resistance; Prorenin; Review; Skeletal Muscle

Indexed keywords

ALISKIREN; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FRUCTOSE; GLUCOSE; INSULIN; LOSARTAN; MESSENGER RNA; PRORENIN; PRORENIN RECEPTOR; AMIDE; CELL SURFACE RECEPTOR; FUMARIC ACID DERIVATIVE; RENIN;

ADIPOCYTE; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PLASMA RENIN ACTIVITY; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROLENTAL FIBROPLASIA; REVIEW; SKELETAL MUSCLE; ADIPOSE TISSUE; ANIMAL; DRUG ANTAGONISM; MALE; METABOLISM; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; PHYSIOLOGY; RAT;

ANIMALIA; RATTUS;

ADIPOSE TISSUE; AMIDES; ANIMALS; FUMARATES; GLUCOSE; INSULIN RESISTANCE; MALE; MUSCLE, SKELETAL; RATS; RATS, INBRED OLETF; RECEPTORS, CELL SURFACE; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 80053114420     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. E. J. Henriksen: Improvement of insulin sensitivity by antagonism of the renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol, 293(3), R974-80 (2007)
2. S. Mottillo, K. B. Filion, J. Genest, L. Joseph, L. Pilote, P. Poirier, S. Rinfret, E. L. Schiffrin and M. J. Eisenberg: The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol, 56(14), 1113-32 (2010)
3. S. I. McFarlane, M. Banerji and J. R. Sowers: Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab, 86(2), 713-8 (2001)
4. S. Yusuf, P. Sleight, J. Pogue, J. Bosch, R. Davies and G. Dagenais: Effectsof an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med, 342(3), 145-53 (2000)
5. B. M. Brenner, M. E. Cooper, D. de Zeeuw, W. F. Keane, W. E. Mitch, H. H. Parving, G. Remuzzi, S. M. Snapinn, Z. Zhang and S. Shahinfar: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med, 345(12), 861-9 (2001)
6. H. H. Parving, F. Persson, J. B. Lewis, E. J. Lewis and N. K. Hollenberg: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med, 358(23), 2433-46 (2008)
7. H. Kobori, M. Nangaku, L. G. Navar and A. Nishiyama: The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev, 59(3), 251-87 (2007)
8. G. Nguyen, F. Delarue, C. Burckle, L. Bouzhir, T. Giller and J. D. Sraer: Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest, 109(11), 1417-27 (2002)
9. F. Suzuki, M. Hayakawa, T. Nakagawa, U. M. Nasir, A. Ebihara, A. Iwasawa, Y. Ishida, Y. Nakamura and K. Murakami: Human prorenin has "gate and handle" regions for its non-proteolytic activation. J Biol Chem, 278(25), 22217-22 (2003)
10. A. Ichihara, Y. Kaneshiro, T. Takemitsu, M. Sakoda, F. Suzuki, T. Nakagawa, A. Nishiyama, T. Inagami and M. Hayashi: Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension, 47(5), 894-900 (2006)
11. A. Ichihara, Y. Kaneshiro, T. Takemitsu, M. Sakoda, T. Nakagawa, A. Nishiyama, H. Kawachi, F. Shimizu and T. Inagami: Contribution of nonproteolytically activated prorenin in glomeruli to hypertensive renal damage. J Am Soc Nephrol, 17(9), 2495-503 (2006)
12. A. Ichihara, M. Hayashi, Y. Kaneshiro, F. Suzuki, T. Nakagawa, Y. Tada, Y. Koura, A. Nishiyama, H. Okada, M. N. Uddin, A. H. Nabi, Y. Ishida, T. Inagami and T. Saruta: Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle " region for nonproteolytic activation of prorenin. J Clin Invest, 114(8), 1128-35 (2004)
13. Y. Nagai, A. Ichihara, D. Nakano, S. Kimura, N. Pelisch, Y. Fujisawa, H. Hitomi, N. Hosomi, H. Kiyomoto, M. Kohno, H. Ito and A. Nishiyama: Possible contribution of the non-proteolytic activation of prorenin to the development of insulin resistance in fructose-fed rats. Exp Physiol, 94(9), 1016-23 (2009)
14. H. Abuissa, P. G. Jones, S. P. Marso and J. H. O'Keefe, Jr.: Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol, 46(5), 821-6 (2005)
15. B. Dahlof, R. B. Devereux, S. E. Kjeldsen, S. Julius, G. Beevers, U. de Faire, F. Fyhrquist, H. Ibsen, K. Kristiansson, O. Lederballe-Pedersen, L. H. Lindholm, M. S. Nieminen, P. Omvik, S. Oparil and H. Wedel: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 359(9311), 995-1003 (2002)
16. T. Shiuchi, T. X. Cui, L. Wu, H. Nakagami, Y. Takeda- Matsubara, M. Iwai and M. Horiuchi: ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO. Hypertension, 40(3), 329-34 (2002)
17. T. Shiuchi, M. Iwai, H. S. Li, L. Wu, L. J. Min, J. M. Li, M. Okumura, T. X. Cui and M. Horiuchi: Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension, 43(5), 1003-10 (2004)
18. Y. S. Kang, M. H. Lee, H. K. Song, Y. Y. Hyun, J. J. Cha, G. J. Ko, S. H. Kim, J. E. Lee, J. Y. Han and D. R. Cha: Aliskiren improves insulin resistance and ameliorates diabetic vascular complications in db/db mice. Nephrol Dial Transplant (2010)
19. Y. F. Dong, L. Liu, K. Kataoka, T. Nakamura, M. Fukuda, Y. Tokutomi, H. Nako, H. Ogawa and S. Kim- Mitsuyama: Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes. Diabetologia, 53(1), 180-91 (2010)
20. M. Iwai, H. Kanno, Y. Tomono, S. Inaba, I. Senba, M. Furuno, M. Mogi and M. Horiuchi: Direct renin inhibition improved insulin resistance and adipose tissue dysfunction in type 2 diabetic KK-A(y) mice. J Hypertens, 28(7), 1471-81 (2010)
21. G. Lastra, J. Habibi, A. T. Whaley-Connell, C. Manrique, M. R. Hayden, J. Rehmer, K. Patel, C. Ferrario and J. R. Sowers: Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression. Endocrinology, 150(6), 2561-8 (2009)
22. Y. Tomono, M. Iwai, S. Inaba, M. Mogi and M. Horiuchi: Blockade of AT1 receptor improves adipocyte differentiation in atherosclerotic and diabetic models. Am J Hypertens, 21(2), 206-12 (2008)
23. J. A. Luetscher, F. B. Kraemer, D. M. Wilson, H. C. Schwartz and M. Bryer-Ash: Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N Engl J Med, 312(22), 1412-7 (1985)
24. D. M. Wilson and J. A. Luetscher: Plasma prorenin activity and complications in children with insulindependent diabetes mellitus. N Engl J Med, 323(16), 1101-6 (1990)
25. K. Kawano, T. Hirashima, S. Mori, Y. Saitoh, M. Kurosumi and T. Natori: Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes, 41(11), 1422-8 (1992)
26. A. Nishiyama, D. M. Seth and L. G . Navar: Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats. Hypertension, 39(1), 129-34 (2002)
27. J. B. Buse, H. N. Ginsberg, G. L. Bakris, N. G. Clark, F. Costa, R. Eckel, V. Fonseca, H. C. Gerstein, S. Grundy, R. W. Nesto, M. P. Pignone, J. Plutzky, D. Porte, R. Redberg, K. F. Stitzel and N. J. Stone: Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation, 115(1), 114-26 (2007)
28. G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, G. Germano, G. Grassi, A. M. Heagerty, S. E. Kjeldsen, S. Laurent, K. Narkiewicz, L. Ruilope, A. Rynkiewicz, R. E. Schmie der, H. A. Boudier, A. Zanchetti, A. Vahanian, J. Camm, R. De Caterina, V. Dean, K. Dickstein, G. Filippatos, C. Funck-Brentano, I. Hellemans, S. D. Kristensen, K. McGregor, U. Sechtem, S. Silber, M. Tendera, P. Widimsky, J. L. Zamorano, S. Erdine, W. Kiowski, E. Agabiti-Rosei, E. Ambrosioni, L. H. Lindholm, M. Viigimaa, S. Adamopoulos, E. Agabiti- Rosei, E. Ambrosioni, V. Bertomeu, D. Clement, S. Erdine, C. Farsang, D. Gaita, G. Lip, J. M. Mallion, A. J. Manolis, P. M. Nilsson, E. O'Brien, P. Ponikowski, J. Redon, F. Ruschitzka, J. Tamargo, P. van Zwieten, B. Waeber and B. Williams: 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens, 25(6), 1105-87 (2007)
29. T. Ogihara, K. Kikuchi, H. Matsuoka, T. Fujita, J. Higaki, M. Horiuchi, Y. Imai, T. Imaizumi, S. Ito, H. Iwao, K. Kario, Y. Kawano, S. Kim-Mitsuyama, G. Kimura, H. Matsubara, H. Matsuura, M. Naruse, I. Saito, K. Shimada, K. Shimamoto, H. Suzuki, S. Takishita, N. Tanahashi, T. Tsuchihashi, M. Uchiyama, S. Ueda, H. Ueshima, S. Umemura, T. Ishimitsu and H. Rakugi: The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res, 32(1), 3-107 (2009)
30. K. Suzuki, O. Nakagawa and Y. Aizawa: Improved early-phase insulin response after candesartan treatment in hypertensive patients with impaired glucose tolerance. Clin Exp Hypertens, 30(5), 309-14 (2008)
31. S. I. McFarlane, A. Kumar and J. R. Sowers: Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol, 91(12A), 30H-37H (2003)
32. O. Iimura, K. Shimamoto, K. Matsuda, A. Masuda, H. Takizawa, K. Higashiura, Y. Miyazaki, A. Hirata, N. Ura and M. Nakagawa: Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives. Am J Hypertens, 8(4 Pt 1), 353-7 (1995)
33. C. Jensen, P. Herold and H. R. Brunner: Aliskiren: the first renin inhibitor for clinical treatment. Nat Rev Drug Discov, 7(5), 399-410 (2008)
34. K. B. Biswas, A. H. Nabi, Y. Arai, T. Nakagawa, A. Ebihara, A. Ichihara, T. Watanabe, T. Inagami and F. Suzuki: Aliskiren binds to renin and prorenin bound to (pro)renin receptor in vitro. Hypertens Res, 33(10), 1053-9 (2010)
35. A. H. Gradman, R. E. Schmieder, R. L. Lins, J. Nussberger, Y. Chiang and M. P. Bedigian: Aliskiren, a novel orally effective renin inhibitor, provides dosedependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation, 111(8), 1012-8 (2005)
36. T. Imanishi, H. Tsujioka, H. Ikejima, A. Kuroi, S. Takarada, H. Kitabata, T. Tanimoto, Y. Muragaki, S. Mochizuki, M. Goto, K. Yoshida and T. Akasaka: Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Hypertension, 52(3), 563-72 (2008)
37. E. Diamanti-Kandarakis, F. N. Economou, S. Livadas, E. Tantalaki, C. Piperi, A. G. Papavassiliou and D. Panidis: Hyperreninemia characterizing women with polycystic ovary syndrome improves after metformin therapy. Kidney Blood Press Res, 32(1), 24-31 (2009)
38. H. Yokota, T. Nagaoka, F. Mori, T. Hikichi, H. Hosokawa, H. Tanaka, Y. Ishida, F. Suzuki and A. Yoshida: Prorenin levels in retinopathy of prematurity. Am J Ophthalmol, 143(3), 531-3 (2007)